Orchid Pharma Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

- **7ACA Project**: Mechanical completion targeted by September 2026 with water trials expected in 1 quarter post that and commercial production following next quarter. The project is strategically critical to enhance backward integration and cost competitiveness. (Page 4, 12, 15) - **Cefiderocol Facility**: Commercial operations commissioning expected by December 2026. API production already underway, with formulation production and market launch planned post-plant readiness. (Page 7, 12) - **FDF Plant at Chennai**: Under development, expected to yield benefits for differentiated product development and long-term competitiveness. (Page 4) - **AMS Division Expansion**: Continuously scaling up with improved operating leverage and cost calibration; new product launches ongoing, including sterile and injectable formulations. (Page 4, 13) Overall, Orchid Pharma is focused on strategic investments in backward integration (7ACA), new product launches (Cefiderocol), and formulation capabilities to change its medium-term earnings profile.

The transcript does not explicitly mention the current or expected order book or pending orders for Orchid Pharma Limited. However, relevant insights include: - Advanced discussions and licensing agreements are underway for Exblifep in more than 10 countries, indicating a pipeline of potential orders beyond existing markets. - Binding and nonbinding term sheets have been signed in key geographies for Exblifep, signaling committed future business. - AMS division sales continue to increase steadily with improving operating leverage, indicating growth in ongoing orders. - The 7ACA project is progressing with mechanical completion targeted by September, which will enhance long-term cost competitiveness and potentially lead to new orders. - Hospital segment and branded formulations targeted at INR20 crores next year, reflecting expected new order inflows in these segments. No specific numeric order book details or pending order values were disclosed in the call.